NCT06050252 RECRUITING Testing the Combination of the Anticancer Drug Durvalumab With Chemotherapy (Gemcitabine and Cisplatin) at Improving Outcomes for High-Risk Resectable Liver Cancer Before Surgery
National Cancer Institute (NCI)
NCT07038343 RECRUITING AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)
Avenzo Therapeutics, Inc.
NCT05564403 ACTIVE NOT RECRUITING Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial)
National Cancer Institute (NCI)
NCT04068194 ACTIVE NOT RECRUITING Testing the Combination of New Anti-cancer Drug Peposertib With Avelumab and Radiation Therapy for Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies
National Cancer Institute (NCI)
NCT02834013 ACTIVE NOT RECRUITING Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
National Cancer Institute (NCI)
NCT05874414 RECRUITING Combination of GNS561 and Trametinib in Patients With Advanced KRAS Mutated Cholangiocarcinoma
Genfit
NCT06501625 RECRUITING Ivosidenib Plus Durvalumab and Gemcitabine/Cisplatin as First-Line Therapy in Participants With Locally Advanced or Metastatic Cholangiocarcinoma With an IDH1 Mutation
Institut de Recherches Internationales Servier
NCT06728410 RECRUITING A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or Rearrangement
Mehmet Akce
NCT04645160 RECRUITING Evaluating Efficacy of Tivozanib (AV-951) in Biliary Tract Cancers
National Cancer Institute (NCI)
NCT07570849 RECRUITING Chidamide Combined With Chemotherapy and Immunotherapy as First-line Treatment for Advanced Intrahepatic Cholangiocarcinoma
Shanghai Zhongshan Hospital
NCT06239194 RECRUITING Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
ModeX Therapeutics, An OPKO Health Company
NCT07569679 RECRUITING Alternating HAIC and Systemic Chemotherapy With or Without Adebrelimab and Apatinib for Unresectable Biliary Tract Cancer
Air Force Military Medical University, China
NCT06441747 RECRUITING Phase II Study of the Combination of Durvalumab (MEDI4736) (PDL1 Inhibitor) and Olaparib (PARP Inhibitor) in Advanced Cholangiocarcinoma After Initial Chemotherapy and Durvalumab (BIL-PPP)
Australasian Gastro-Intestinal Trials Group
NCT05286814 RECRUITING PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma
National Cancer Institute (NCI)
NCT03482102 ACTIVE NOT RECRUITING Durvalumab (MEDI4736) and Tremelimumab and Radiation Therapy in Hepatocellular Carcinoma and Biliary Tract Cancer
Massachusetts General Hospital
NCT06503146 RECRUITING 18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection
National Cancer Institute (NCI)
NCT04421820 RECRUITING BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours
Bold Therapeutics, Inc.
NCT07030140 RECRUITING Phase II Study of Neoadjuvant Tislelizumab Plus Radiotherapy and GP Chemotherapy for Borderline/Unresectable Hilar Cholangiocarcinoma
Jinbo Yue
NCT07561775 NOT YET RECRUITING Adebrelimab Plus S-1 for Resected Cholangiocarcinoma
Xingjun Guo
NCT07478523 RECRUITING FAPI-PET Value for the Initial Screening of Pancreatic and Biliary Cancers
University Hospital, Bordeaux
NCT03878095 ACTIVE NOT RECRUITING Testing Olaparib and AZD6738 in IDH1 and IDH2 Mutant Tumors
National Cancer Institute (NCI)
NCT06921928 RECRUITING Study for AZD4360 in Participants With Advanced Solid Tumours
AstraZeneca
NCT04891289 RECRUITING Gemcitabine and Oxaliplatin Chemotherapy With or Without a Floxuridine and Dexamethasone Pump in People With Cholangiocarcinoma That Cannot Be Removed With Surgery
Memorial Sloan Kettering Cancer Center
NCT05655949 RECRUITING Y-90 With Durvalumab/Gem/Cis in Intrahepatic Cholangio
Beth Israel Deaconess Medical Center
NCT03942328 RECRUITING Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer
Mayo Clinic
NCT05969860 RECRUITING At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
Mayo Clinic
NCT05775159 RECRUITING Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer
AstraZeneca
NCT06855225 NOT YET RECRUITING A Phase II Study of Single Tremelimumab With Regular Interval Durvalumab Plus Gemcitabine and Cisplatin in Locally Advanced Unresectable/Metastatic Combined Hepatocellular-cholangiocarcinoma
Mehmet Akce
NCT06777316 ACTIVE NOT RECRUITING A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors
Cogent Biosciences, Inc.
NCT06708663 RECRUITING HX009+ IN10018 With or Without Standard Chemotherapy for Advanced Solid Tumours
Hangzhou Hanx Biopharmaceuticals, Ltd.
NCT05967182 RECRUITING A Single-Arm Study of Pembrolizumab With Gemcitabine and Cisplatin as Perioperative Therapy for Potentially Resectable Intrahepatic Cholangiocarcinoma
M.D. Anderson Cancer Center
NCT06638931 RECRUITING Agnostic Therapy in Rare Solid Tumors
Instituto do Cancer do Estado de São Paulo
NCT07530445 RECRUITING Phase II Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Albumin-Bound Paclitaxel and Lenvatinib as Second-Line Therapy for Unresectable or Metastatic Biliary Tract Cancer
Sun Yat-sen University
NCT07522476 NOT YET RECRUITING A Clinical Study to Evaluate the Efficacy and Safety of VG2025 in Intrahepatic Cholangiocarcinoma
Virogin Biotech Ltd.
NCT06431490 RECRUITING A Study of TQB2102 for Injection in the Treatment of HER2-positive Biliary Tract Cancer
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
NCT07514533 NOT YET RECRUITING The Efficacy and Safety of Pucotenlimab (PD-1) Combined With Becotatugvedotin (EGFR-ADC) in Advanced Cholangiocarcinoma
Sir Run Run Shaw Hospital
NCT05733598 RECRUITING Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC
Replimune, Inc.
NCT07506057 RECRUITING Trastuzumab in Combination With Serplulimab and Chemotherapy for the Treatment of HER2-overexpressing Unresectable Locally Advanced or Metastatic Biliary Tract Cancer or Urothelial Carcinoma After Failure of Standard Therapy
Xiujuan Qu
NCT07450976 RECRUITING A Study of SHR-A1904 in Previous Systemic Treatment Failed Biliary Tract Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
NCT06178445 ACTIVE NOT RECRUITING Efficacy and Safety of GemCis Plus Trastuzumab Plus Pembrolizumab in Previously Untreated HER2-positive Biliary Tract Cancer
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
NCT05849480 RECRUITING A Study of CDX-1140, a CD40 Agonist, in Combination With Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects With Biliary Tract Carcinoma (BTC)
National Cancer Institute (NCI)
NCT07260175 RECRUITING Phase II Study Evaluating Ivosidenib Maintenance After SOC Adjuvant Chemotherapy in Curative mIDH1 Cholangiocarcinoma
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
NCT05489211 RECRUITING Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
AstraZeneca
NCT07169734 RECRUITING A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors
Alentis Therapeutics AG
NCT07471165 NOT YET RECRUITING A Prospective, Single-Arm, Phase II Study: PD-L1 Monoclonal Antibody + Chemoradiotherapy as Bridge Therapy to Liver Transplantation for Locally Advanced Perihilar Cholangiocarcinoma (ACHIEVE-LT)
The First Affiliated Hospital with Nanjing Medical University
NCT06858735 RECRUITING HYPERION CCA: a Phase 2 Trial of Systemic Therapy With or Without Liver-directed Radiation Therapy for Patients With Advanced Intrahepatic Cholangiocarcinoma
M.D. Anderson Cancer Center
NCT06859684 RECRUITING Hepatic Arterial Infusion Chemotherapy (HAIC) Combined With Durvalumab and Lenvatinib in Patients With Locally Advanced or Metastatic Intrahepatic Cholangiocarcinoma: a Phase 2 Study(HAIC-quad Trial)
West China Hospital
NCT02568267 ACTIVE NOT RECRUITING Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
Hoffmann-La Roche
NCT07282912 RECRUITING Trial Comparing Standard of Care Therapy With and Without Sequential Cytoreductive Intervention for Patients With Metastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid (ctDNA) Levels
Yale University
NCT06938321 RECRUITING A Study of AK130 in Combination With AK112 for the Treatment of Advanced Biliary Tract Cancer
Akeso
NCT06789848 RECRUITING Ligufalimab and Cadonilimab in Advanced Liver Cancers
University of Texas Southwestern Medical Center
NCT04969887 ACTIVE NOT RECRUITING Combination Immunotherapy in Rare Cancers Under InvesTigation
Olivia Newton-John Cancer Research Institute
NCT07432568 NOT YET RECRUITING A Study of Liposomal Irinotecan Plus 5-FU/LV HAIC With Lenvatinib and a PD-1 Inhibitor in Advanced ICC
Tianjin Medical University Cancer Institute and Hospital
NCT04430738 ACTIVE NOT RECRUITING Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers
Seagen, a wholly owned subsidiary of Pfizer
NCT06178588 ACTIVE NOT RECRUITING Sacituzumab Govitecan for the Treatment for Patients With Locally Advanced, Recurrent, or Metastatic Cholangiocarcinoma
University of Kansas Medical Center
NCT03212274 ACTIVE NOT RECRUITING Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations
National Cancer Institute (NCI)
NCT07146646 RECRUITING Trifluridine/Tipiracil + Oxaliplatin in Participants With Advanced or Metastatic Biliary Tract Cancer
Case Comprehensive Cancer Center
NCT05994001 ACTIVE NOT RECRUITING Candonilimab in Combination With LM-302 for Claudin 18.2 Positive-advanced Biliary Tract Cancer After Failure of Standard of Chemotherapy and PD1/PD-L1 Antibody
Shanghai Zhongshan Hospital
NCT06219941 RECRUITING AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
AstraZeneca
NCT05430698 RECRUITING PD-1 Antibody Plus GEMOX as Postoperative Adjuvant Therapy in Perihilar Cholangiocarcinoma
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
NCT07223307 RECRUITING REGULUS: MRI-guided Adaptive SABR for Liver Cancers
Stanford University
NCT07201519 RECRUITING Study of Safety/Feasibility of a Hybrid Model of Tertiary and Community Delivery of Hepatic Artery Infusion Chemotherapy
Michael J Cavnar, MD
NCT06313203 RECRUITING HAI-Floxuridine, or SIRT, Combined With Gemox For Patients With Intra-Hepatic Cholangiocarcinoma Not Amenable to Resection (TOMCAT)
Oslo University Hospital
NCT07369791 NOT YET RECRUITING Nivolumab Plus Relatlimab and Gemcitabine/Cisplatin as First-Line Treatment in Advanced Biliary Tract Cancer.
National Health Research Institutes, Taiwan
NCT04005339 ACTIVE NOT RECRUITING NAPOLI-2: Fluorouracil, Leucovorin, and Nanoliposomal Irinotecan in Biliary Cancer
Georgetown University
NCT04781192 ACTIVE NOT RECRUITING The Purpose of This Trial is to Determine if Regorafenib Plus Durvalumab (MEDI4736) is Safe and Effective in Treatment of Chemo Refractory Advanced Biliary Tract Cancers
University of Kansas Medical Center
NCT06048133 RECRUITING Study of Gemcitabine, Cisplatin, AB680 and AB122 During First Line Treatment of Advanced Biliary Tract Cancers (QUIC)
Nataliya Uboha
NCT06428409 RECRUITING A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)
Merck Sharp & Dohme LLC
NCT05170438 ACTIVE NOT RECRUITING Lenvatinib Plus Paclitaxel for Patients With Advanced Biliary Tract Cancer Who Failed to Gemcitabine-based Treatment
National Health Research Institutes, Taiwan
NCT06548412 RECRUITING CTX-009 With Gemcitabine, Cisplatin, and Durvalumab as First-line Therapy in Patients With Unresectable or Metastatic Biliary Tract Cancers
M.D. Anderson Cancer Center
NCT07353827 NOT YET RECRUITING FOLFOX-HAIC Combined With Donafenib and Pucotenlimab as First-Line Treatment for Unresectable Intrahepatic Cholangiocarcinoma
Sun Yat-sen University
NCT07351591 NOT YET RECRUITING A Phase II Trial of Organoid Drug Sensitivity Testing to Guide Therapy in Unresectable Biliary Tract Cancers
Eastern Hepatobiliary Surgery Hospital
NCT06439485 RECRUITING Phase I/II Trial of Pemigatinib in Combination With Atezolizumab and Bevacizumab for Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion
M.D. Anderson Cancer Center
NCT06399757 RECRUITING A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors
Apollo Therapeutics Ltd
NCT03364530 RECRUITING Hepatic Arterial Infusion of Gemcitabine-oxaliplatin for Second-line Therapy in Non-metastatic Unresectable Intra-hepatic Cholangiocarcinoma
University Hospital, Montpellier
NCT05727176 RECRUITING Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement
Taiho Oncology, Inc.
NCT07296666 NOT YET RECRUITING Adjuvant Chemotherapy for BTC Based on 3D-PTA
Fudan University
NCT07291947 RECRUITING PULSAR Combined With Immunotherapy and Chemotherapy
Wang Xin
NCT06730009 RECRUITING Phase I/II Study: Allogeneic NK-cell Therapy With Chemotherapy for Post-Surgery PDA or Cholangiocarcinoma Patients
Medigen Biotechnology Corporation
NCT07282262 RECRUITING An Exploratory Study on the Use of Ivosidenib for the Precise Treatment of Advanced Biliary Tract Malignancies With IDH1 Mutations in the Later Line of Therapy.
Peking Union Medical College Hospital
NCT06943521 RECRUITING A Study of MT-4561 in Patients With Various Advanced Solid Tumors
Tanabe Pharma America, Inc.
NCT06081829 ACTIVE NOT RECRUITING A Phase 2 Study of Ivosidenib in Previously Treated Japanese Subjects With Nonresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation
Servier
NCT05174650 ACTIVE NOT RECRUITING Treatment of Atezolizumab and Derazantinib in Patients With Advanced iCCA With FGFR2 Fusions/Rearrangements
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
NCT04238637 ACTIVE NOT RECRUITING Immunotherapy Combined With Y-90 SIRT Therapy in Advanced Stage Intrahepatic Biliary Tract Cancer (BTC)
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
NCT07267078 RECRUITING Tuvonralimab and Iparomlimab Based Regimens for the Neoadjuvant Treatment of Biliary Tract Cancer
Peking Union Medical College Hospital
NCT06440993 RECRUITING Durvalumab + Intraductal Radiofrequency Ablation (ID-RFA) in Extrahepatic Cholangiocarcinoma
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
NCT06925516 RECRUITING A Trial of Apatinib and Adebrelimab in Combination With Chemotherapy in Patients With Unresectable ICC
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
NCT07243951 NOT YET RECRUITING Phase II Clinical Study on the Efficacy and Safety of the Combination of Cadonilimab and Capecitabine in Adjuvant Therapy for Combined Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma
Shanghai Zhongshan Hospital
NCT04175912 ACTIVE NOT RECRUITING Testing the Combination of Pevonedistat With Chemotherapy for Bile Duct Cancer of the Liver
National Cancer Institute (NCI)
NCT06529718 RECRUITING Testing Ivonescimab Versus FOLFOX in Advanced Biliary Tract Cancer Patients
UNICANCER
NCT05482893 RECRUITING Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)
Phanes Therapeutics
NCT02628067 ACTIVE NOT RECRUITING Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)
Merck Sharp & Dohme LLC
NCT05297903 ACTIVE NOT RECRUITING XmAb20717 in Advanced Biliary Tract Cancers
Abramson Cancer Center at Penn Medicine
NCT07159217 NOT YET RECRUITING Disitamab Vedotin Plus Lenvatinib and PD-1 Inhibitors for Treating HER2-positive Advanced Biliary Tract Cancer
Peking Union Medical College Hospital
NCT07159204 RECRUITING Paclitaxel mIcelle Later-line cOmbined immunoTherapy for Biliary Tract Cancer
Peking Union Medical College Hospital
NCT07151872 NOT YET RECRUITING Combination of QLS31905 and Chemotherapy ± QL2107 in Patients With CLDN18.2-positive Advanced Biliary Tract Cancer
Qilu Pharmaceutical Co., Ltd.
NCT07152769 NOT YET RECRUITING Iparomlimab and Tuvonralimab Combined With GC in Advanced ICC
Fudan University
NCT07147088 NOT YET RECRUITING Cryoablation Combined With SHR-1701 Plus Famitinib in Patients With Advanced Intrahepatic Cholangiocarcinoma.
Fudan University
NCT03907852 ACTIVE NOT RECRUITING Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer
TCR2 Therapeutics
NCT05451849 ACTIVE NOT RECRUITING A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer
TCR2 Therapeutics
NCT07135544 RECRUITING A Single-arm, Multicenter, Exploratory Study of Adebrelimab Combined With Apatinib and Systemic Chemotherapy for Initially Unresectable Biliary Tract Cancer
Yongjun Chen
NCT06057571 ACTIVE NOT RECRUITING Study of TT-00420 (Tinengotinib) in Subjects With Cholangiocarcinoma Who Failed or Relapsed to Chemotherapy and FGFR Inhibitor
TransThera Sciences (Nanjing), Inc.
NCT07129018 NOT YET RECRUITING Trastuzumab Rezetecan Combined With Pertuzumab and Iparomlimab and Tuvonralimab for Biliary Tract Cancer
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
NCT07128290 NOT YET RECRUITING PErioperative CISGEM + Rilvegostomig in High-Risk Resectable Intra Hepatic CholangioCarcinoma
Federation Francophone de Cancerologie Digestive
NCT07105748 RECRUITING HAIC Combined With Camrelizumab Plus Rivoceranib for Advanced Mixed Hepatocellular-cholangiocarcinoma (HCC-CCA)
Fudan University
NCT07070700 RECRUITING Cryoablation Combined With Lenvatinib Plus QL1706 (Iparomlimab/Tuvonralimab) in Patients With Advanced Intrahepatic Cholangiocarcinoma
Fudan University
NCT05265208 RECRUITING Selective Internal Radiation Therapy and Capecitabine (Chemotherapy) Treatment for Liver Cancer
Center Eugene Marquis
NCT07105852 RECRUITING Exploring the Safety and Efficacy of Sacituzumab Tirumotecan Combined With Pucotenlimab in the Treatment of Advanced Cholangiocarcinoma
Sir Run Run Shaw Hospital
NCT02711553 ACTIVE NOT RECRUITING A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer
Eli Lilly and Company
NCT07099794 NOT YET RECRUITING A Randomized, Two-cohort, Prospective Phase II Clinical Study of the Second-line Treatment of Advanced Biliary System Tumors With Liposomal Irinotecan (II) Combination Regimen
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
NCT07063888 RECRUITING A Prospective Phase II Study of Postoperative Concurrent Chemoradiotherapy in Patients With Intrahepatic Cholangiocarcinoma
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
NCT05422690 RECRUITING The Purpose of This Research Study is to See if Combining Gemcitabine, Cisplatin and Durvalumab Chemotherapy Treatments With a Direct Tumor Therapy Yittrium-90 (Y-90) Will Work Better Together to Shrink Tumors and Control Cancer
Inova Health Care Services
NCT03801083 RECRUITING Adoptive Transfer of Tumor Infiltrating Lymphocytes for Biliary Tract Cancers
Udai Kammula
NCT06978114 RECRUITING A Study of BL-B01D1+PD-1/PD-L1 Monoclonal Antibody in Patients With Advanced Biliary Tract Cancer
Sichuan Baili Pharmaceutical Co., Ltd.
NCT05451043 RECRUITING Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED)
AHS Cancer Control Alberta
NCT02632305 ACTIVE NOT RECRUITING A Study to See the Effects That a New Combination of the Three Drugs, Nab-paclitaxel, Gemcitabine, and Cisplatin Has on Biliary Tract Cancer
AHS Cancer Control Alberta
NCT07025174 RECRUITING Sequential Anti-Angiogenic Therapy After Immunotherapy in Advanced Biliary Tract Cancer
First Affiliated Hospital of Zhejiang University
NCT05712356 ACTIVE NOT RECRUITING A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors
Lisata Therapeutics, Inc.
NCT07003815 NOT YET RECRUITING Envafolimab With Chemotherapy and Simvastatin in Advanced Biliary Tract Cancer
Tongji Hospital
NCT06199895 RECRUITING Clinical Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Patients With Taxans-resistant Pancreatic Adenocarcinoma, Cholangiocarcinoma, Lung Cancer, Gastric Cancer, Esophageal Carcinoma, or Breast Cancer
Liu Huang
NCT06993025 NOT YET RECRUITING Ivonescimab in Combination With Liposomal Irinotecan and 5-FU/LV in Potentially Resectable Biliary Tract Malignancies
Tianjin Medical University Cancer Institute and Hospital
NCT04941287 ACTIVE NOT RECRUITING Testing A New Combination of Anti-cancer Immune Therapies, Atezolizumab and CDX-1127 (Varlilumab) With or Without the Addition of a Third Anti-cancer Drug, Cobimetinib, for Advanced-Stage Biliary Tract Cancer
National Cancer Institute (NCI)
NCT05724563 ACTIVE NOT RECRUITING Domvanalimab and Zimberelimab in Advanced Liver Cancers
University of Texas Southwestern Medical Center
NCT05039892 NOT YET RECRUITING Efficacy and Safety of 3D185 Monotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Cholangiocarcinoma
3D Medicines (Beijing) Co., Ltd.
NCT06963060 ENROLLING BY INVITATION Gem+Nab-P+LEN+TIS for Advanced Unresectable BTC (GALENT-BT)
Wei Gong
NCT06438822 RECRUITING Cadonilimab Combined With Liposomal Irinotecan Plus Leucovorin and Fluorouracil for Advanced Cholangiocarcinoma
West China Hospital
NCT06956716 RECRUITING Personalized Tumor Neoantigen mRNA Therapy for Advanced Intrahepatic Cholangiocarcinoma
Zhejiang University
NCT06946849 NOT YET RECRUITING Second-line Regimen Combined With Radiotherapy Versus Without Radiotherapy in Patients With Locally Advanced/Oligometastatic ICC After Failure of First-line Treatment：an Open-label, Randomized, Controlled Phase II Clinical Study
Shanghai Zhongshan Hospital
NCT04251715 ACTIVE NOT RECRUITING mFOLFIRINOX Followed by Hepatic Arterial Infusion of Floxuridine and Dexamethasone With Systemic mFOLFIRI for Unresectable Liver-dominant Intrahepatic Cholangiocarcinoma
OHSU Knight Cancer Institute
NCT04634058 ACTIVE NOT RECRUITING PD-L1 Antibody Combined With CTLA-4 Antibody for Patients With Advanced Intrahepatic Cholangiocarcinoma Who Progressed After Standard Treatment
Shanghai Zhongshan Hospital
NCT06919848 NOT YET RECRUITING Oncolytic Virus H101 Combined With Lenvatinib Plus Toripalimab Compared With FOLFOX in Patients With Advanced Biliary Tract Cancer (OPTIONS-06)
Fudan University
NCT06620848 RECRUITING A Study of HRS-4642 Monotherapy or in Combination With Adebrelimab in the Treatment of Advanced Biliary Tract Tumors.
Shanghai Zhongshan Hospital
NCT06903273 NOT YET RECRUITING Neoadjuvant Tislelizumab, Gemcitabine, Cisplatin and S-1 for Resectable High-risk Cholangiocarcinoma
National Cheng-Kung University Hospital
NCT06901622 ENROLLING BY INVITATION Camrelizumab and Chemotherapy With or Without Anlotinib as First-line Treatment for Advanced Gallbladder Cancer and Extrahepatic Cholangiocarcinoma
The First Affiliated Hospital of Zhengzhou University
NCT05784688 RECRUITING Study of TU2218 in Combination With KEYTRUDA®(Pembrolizumab) in Patients With Advanced Solid Tumors
TiumBio Co., Ltd.
NCT06888063 RECRUITING Additional Chemotherapy Administered Directly Into the Liver Using a Chemo Pump in Patients With Bile Duct Cancer Inside the Liver Treatable by Surgery
Erasmus Medical Center
NCT04802876 ACTIVE NOT RECRUITING Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors
SOLTI Breast Cancer Research Group
NCT06778031 RECRUITING A Clinical Study of SHR-A1811 in the Treatment of HER2-positive Locally Advanced or Metastatic Biliary Tract Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
NCT06208462 RECRUITING Neoadjuvant Therapy of HAIC（GEMOX） Combined With Adebrelimab and Lenvatinib for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors
The First Affiliated Hospital with Nanjing Medical University
NCT06852287 RECRUITING Phase II Clinical Study of GemOX Hepatic Arterial Infusion Combined with Lenvatinib and Toripalimab for Advanced and Unresectable Intrahepatic Cholangiocarcinoma and Gallbladder Cancer
Tianjin Medical University Cancer Institute and Hospital
NCT05010681 RECRUITING Lenvatinib Plus Sintilimab in Patients With Immune Checkpoint Inhibitor Previously Treated Advanced Liver Cancer
Fudan University
NCT04299581 RECRUITING Cryoablation Combined with Anti-PD-1 Antibody in Patients with Advanced Intrahepatic Cholangiocarcinoma
Fudan University
NCT04954781 RECRUITING TACE Combined With Tislelizumab in Patients With Advanced Intrahepatic Cholangiocarcinoma
Fudan University
NCT05557578 RECRUITING GOT Applied As Neoadjuvant Regimen for Patients of Resectable ICC with High-risk Factors of Recurrence
Zhejiang Cancer Hospital
NCT05532059 RECRUITING Lenvatinib, Tislelizumab Plus Gemcitabine and Cisplatin (GPLET) in Patients with Advanced Cholangiocarcinoma
Second Affiliated Hospital, School of Medicine, Zhejiang University
NCT01868490 ENROLLING BY INVITATION The Adoptive Immunotherapy for Solid Tumors Using Modified Autologous CIK Cells
Siriraj Hospital
NCT06792435 RECRUITING XNW27011 Study of Advanced Solid Tumor Subjects Who Failed Standard Therapies.
Evopoint Biosciences Inc.
NCT05749900 RECRUITING First-line Trastuzumab, Gemcitabine, Cisplatin and Nivolumab in Advanced HER2- Positive Biliary Tract Cancer: a Multicenter, Open-label, Single-arm Phase Ib/II Trial (HERBOT)
Yonsei University
NCT05222971 RECRUITING Olaparib With or Without Durvalumab for DDR Gene Mutated Biliary Tract Cancer Following Platinum-based Chemotherapy
Asan Medical Center
NCT04308174 ACTIVE NOT RECRUITING Neoadjuvant Gemcitabine Plus Cisplatin With or Without Durvalumab in Resectable Biliary Tract Cancer
Asan Medical Center
NCT06465563 RECRUITING Adebrelimab With or Without SHR-8068 in Combination With Cisplatin Plus Gemcitabine as First-line Treatment in Patients With Advanced Biliary Tract Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
NCT06607276 RECRUITING Phase 2 Trial of Adjuvant Adebrelimab Combined With Capecitabine in High-Risk Resected Cholangiocarcinoma: ACHIEVE
The First Affiliated Hospital with Nanjing Medical University
NCT06664021 RECRUITING Exploring the Efficacy and Safety of Tislelizumab in Combination With S-1 in the Treatment of Patients With Postoperative Recurrent High-risk Intrahepatic Cholangiocarcinoma
Anhui Provincial Hospital
NCT06274879 NOT YET RECRUITING Safety of Biliary Intraductal Radiofrequency Ablation in Patients With Unresectable Extrahepatic Biliary Tract Cancer
Insel Gruppe AG, University Hospital Bern
NCT03368963 ACTIVE NOT RECRUITING TAS102 in Combination With NAL-IRI in Advanced GI Cancers
Emory University
NCT04295317 ACTIVE NOT RECRUITING PD-1 Antibody (SHR-1210) Plus Capecitabine in Patients with Intrahepatic Cholangiocarcinoma After Surgery
Shanghai Zhongshan Hospital
NCT06746480 RECRUITING Clinical Study of VG161 in Advanced Intrahepatic Cholangiocarcinoma
CNBG-Virogin Biotech (Shanghai) Ltd.
NCT06654947 NOT YET RECRUITING A Single-arm, Open-label, Prospective Clinical Study of Surufatinib Combined With Immunotherapy and Chemotherapy for Unresectable or Metastatic Biliary Tract Cancer.
Fujian Cancer Hospital
NCT06730581 NOT YET RECRUITING Utidelone Capsule Monotherapy for Patients with Advanced Solid Tumors
Beijing Biostar Pharmaceuticals Co., Ltd.
NCT06721286 RECRUITING Toripalimab Combined With Gemcitabine and Cisplatin (GemCis) as Preoperative Neoadjuvant Therapy for Resectable Intrahepatic Cholangiocarcinoma
Tianjin Medical University Cancer Institute and Hospital
NCT06717464 ACTIVE NOT RECRUITING Toripalimab Combined With Capecitabine as Postoperative Adjuvant Therapy for Patients With Resectable Advanced Extrahepatic Biliary Tract Cancer
Tianjin Medical University Cancer Institute and Hospital
NCT06708858 RECRUITING Phase Ⅱ Clinical Study of Surufatinib Combined With Gemcitabine and Cisplatin Plus Durvalumab/Pembrolizumab Regimen in the Treatment of Advanced Biliary Tract Cancer
Dai, Guanghai
NCT06239532 ACTIVE NOT RECRUITING HAIC Sequential TAE Combined With Tislelizumab and Surufatinib in Unresectable Intrahepatic Cholangiocarcinoma
Qilu Hospital of Shandong University
NCT06341764 RECRUITING Neo-adjuvant Chemo and Immunotherapy in the Pre-operAtive Treatment of Locally Advanced CholangIOcarciNoma
National Cancer Institute, Naples
NCT06192797 RECRUITING Combined HAIC, Lenvatinib and Pucotenlimab As Conversion Therapy for Unresectable Intrahepatic Cholangiocarcinoma
Tongji Hospital
NCT06648525 NOT YET RECRUITING Adebrelimab Combined with Irinotecan Liposomes, 5-FU, CF ± Lenvatinib As First-line Treatment for Advanced ICC
Harbin Medical University
NCT04913337 ACTIVE NOT RECRUITING Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies
NGM Biopharmaceuticals, Inc
NCT06569225 NOT YET RECRUITING Gemcitabine/Cisplatin/Nab-Paclitaxel and Rilvegostomig in Resectable iCCA
University Health Network, Toronto
NCT06567600 NOT YET RECRUITING Low-dose Gemcitabine and Cisplatin and PD-1/PD-L1 Antibody Therapy in Intrahepatic Cholangiocarcinoma
Third Affiliated Hospital, Sun Yat-Sen University
NCT05223816 RECRUITING An Open-Label, Multiple-Center, Phase IIa/IIb Clinical Trial to Evaluate the Efficacy, Safety and Tolerability of VG161 as Monotherapy and in Combination With Nivolumab for Treatment of Patients With Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma
Virogin Biotech Canada Ltd
NCT06530823 NOT YET RECRUITING Pemigatinib Combined With Durvalumab for Previously Treated Biliary Tract Carcinoma
Eastern Hepatobiliary Surgery Hospital
NCT06531291 NOT YET RECRUITING Surufatinib Combined With Serplulimab and Standard Chemotherapy as First-line Treatment in Advanced Solid Tumors With Neuroendocrine Differentiation
RenJi Hospital
NCT03991832 RECRUITING Study of Olaparib and Durvalumab in IDH-Mutated Solid Tumors
University Health Network, Toronto
NCT06502080 NOT YET RECRUITING Consolidative Radiotherapy (CSRT) in Patients With Oligometastatic/Locally Advanced Unresectable Bilary Tract Cancer (BTC)
Shanghai Zhongshan Hospital
NCT06413745 RECRUITING Phase II Clinical Study of SHR-A1811 in Patients With HER2 Expression / Amplification of Locally Advanced Unresectable or Recurrent Metastatic Biliary Tract Cancer
Jiangsu HengRui Medicine Co., Ltd.
NCT06490107 ACTIVE NOT RECRUITING Durvalumab Combined With S-1 as Adjuvant Therapy of Resectable BTC
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
NCT06298968 RECRUITING Combined Therapy Using Gemcitabine and Cisplatin Chemotherapy, Lenvatinib and Adebrelimab for Patients With Advanced and Unresectable Intrahepatic Cholangiocarcinoma
Nanfang Hospital, Southern Medical University
NCT06375915 RECRUITING Precision Medicine in Patients With Unresectable CholAngiocarcinoma: RadioEmbolization and Combined Biological Therapy
Francesco De Cobelli
NCT06389500 NOT YET RECRUITING HAIC+Adebrelimab+Lenvatinib for Conversion Treatment of Potentially Resectable, Locally Advanced Biliary Tract Cancer
Harbin Medical University
NCT06280508 RECRUITING Chemotherapy Combined With Adebrelimab and Apatinib as the Perioperative Treatment in Patients With Biliary Tract Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
NCT06375642 NOT YET RECRUITING A Single Arm, Single Centered Phase II Trial on the Combination of Adebrelimab, Surufatinib and Irinotecan Liposome-based HAIC in Advanced iCC
Tianjin Medical University Cancer Institute and Hospital
NCT06296563 RECRUITING Perioperative Treatment of Resectable Intrahepatic Cholangiocarcinoma With the Combination of Adebrelimab and Apatinib and HAIC
Lei ZHAO
NCT06320301 RECRUITING Adebrelimab and a TKI in Combination With GEMOX in First-line Treatment of Advanced Biliary Tract Cancers (BTC)
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
NCT05678270 RECRUITING A Study of ICP-192 in Patients With FGFR2-Rearranged Unresectable or Metastatic Intrahepatic Cholangiocarcinoma
Beijing InnoCare Pharma Tech Co., Ltd.
NCT06033118 NOT YET RECRUITING Gemox Combined With Anlotinib and Sintilimab in Advanced cHCC-ICC
Sichuan University
NCT05985707 NOT YET RECRUITING KN026 Plus Chemotherapy ± KN-046 in HER2 Positive Colorectal Cancer and Biliary Carcinoma
Peking University Cancer Hospital & Institute
NCT05978609 RECRUITING Cadonilimab With Chemotherapy in Treating Advanced Biliary Cancer
West China Hospital
NCT07599995 NOT YET RECRUITING Gemcitabine-Cisplatin Plus Envafolimab in Resectable Biliary Tract Malignancies
Sir Run Run Shaw Hospital
NCT05921760 TERMINATED Ivosidenib, Nivolumab, and Ipilimumab Combination in Previously Treated Subjects With Nonresectable or Metastatic IDH1 Mutant Cholangiocarcinoma
Servier Bio-Innovation LLC
NCT04834674 COMPLETED DEB-TACE Combined With Apatinib and PD-1 for the Treatment of Intrahepatic Cholangiocarcinoma
Sichuan Cancer Hospital and Research Institute
NCT04301778 COMPLETED Durvalumab and SNDX-6532 Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarcinoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT02829918 COMPLETED Study of Nivolumab in Patients With Advanced Refractory Biliary Tract Cancers
H. Lee Moffitt Cancer Center and Research Institute
NCT04238715 COMPLETED A Study of E7090 in Participants With Unresectable Advanced or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor (FGFR) 2 Gene Fusion
Eisai Co., Ltd.
NCT04526106 COMPLETED REFOCUS: A First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With ICC and Other Advanced Solid Tumors
Elevar Therapeutics
NCT04233567 COMPLETED Infigratinib for the Treatment of Advanced or Metastatic Solid Tumors in Patients With FGFR Gene Mutations
Sameek Roychowdhury
NCT05000294 SUSPENDED Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types
University of Florida
NCT03785873 COMPLETED Phase Ib/II Trial of Nal-Irinotecan and Nivolumab as Second-Line Treatment in Patients With Advanced Biliary Tract Cancer
University of Michigan Rogel Cancer Center
NCT03693807 COMPLETED A Study of the Use of the Medtronic Pump and Codman Catheter to Give Chemotherapy to Patients With Colorectal Carcinoma or Cholangiocarcinoma
Memorial Sloan Kettering Cancer Center
NCT06739252 TERMINATED Perioperative Treatment of High-risk Resectable CCA With HAIC Plus A+T: Neobrave CCA
Peking University
NCT05641896 COMPLETED Study of [18F]FAPI-74 PET in Patients With Gastrointestinal Cancers
SOFIE
NCT05512377 TERMINATED Brightline-2: A Study to Test Whether Brigimadlin (BI 907828) Helps People With Cancer in the Biliary Tract, Pancreas, Lung or Bladder
Boehringer Ingelheim
NCT05254847 COMPLETED Capecitabine Combined With Lenvatinib and Tislelizumab as Adjuvant Treatment After Resection in Patients With BTC
Fudan University
NCT05348811 COMPLETED HAIC Combined With Donafenib and Sintilimab for Unresectable ICC
Zhongda Hospital
NCT04203160 TERMINATED Gemcitabine and Cisplatin With or Without CPI-613 as First Line Therapy for Patients With Advanced Unresectable Biliary Tract Cancer (BilT-04)
University of Michigan Rogel Cancer Center
NCT07304388 COMPLETED HAIC Plus Systemic Chemotherapy, Lenvatinib and Toripalimab in Advanced ICC
Sun Yat-sen University
NCT05024513 COMPLETED Biliary Drainage Plus HAIC in Locally Advanced pCCA
Peking University
NCT05998447 TERMINATED GEN-001 Plus Pembrolizumab for Patients With Advanced Refractory Biliary Tract Cancer
Genome & Company
NCT04779151 TERMINATED Basket Trial Exploring the Efficacy and Safety of the Combination of Niraparib and Dostarlimab
Gustave Roussy, Cancer Campus, Grand Paris
NCT05194735 TERMINATED Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors
Alaunos Therapeutics
NCT05328167 COMPLETED Contrast-Enhanced Ultrasound for the Prediction of Bile Duct Cancer Response to Radioembolization Treatment
Thomas Jefferson University
NCT05220722 TERMINATED Pressure Enabled Delivery of SD-101 With Checkpoint Blockade for Primary Liver Tumors
TriSalus Life Sciences, Inc.
NCT03044587 COMPLETED Nal-IRI With 5-fluorouracil (5-FU) and Leucovorin or Gemcitabine Plus Cisplatin in Advanced Biliary-tract Cancer
AIO-Studien-gGmbH
NCT05052099 COMPLETED Phase Ib/II Single-arm Study of mFOLFOX6, Bevacizumab and Atezolizumab in Advanced Biliary Tract Cancer
University Hospital, Essen
NCT03929666 COMPLETED A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer
Jazz Pharmaceuticals
NCT06690281 WITHDRAWN A Phase II Study of Adjuvant Immunotherapy Targeting KRAS G12D, KRAS G12V, or TP53 R175H for Participants With Advanced Gastrointestinal Malignancies
National Cancer Institute (NCI)
NCT04264260 COMPLETED Evaluation the Palliative Effects of Colchicine on Primary Hepatic Malignant Tumors Unable to Receive Curative Treatment
Kaohsiung Medical University Chung-Ho Memorial Hospital
NCT06084689 WITHDRAWN Targeting MDMD and PD1 in Tumors With Tertiary Lymphoid Structures
Institut Bergonié
NCT03579771 COMPLETED Gemcitabine, Cisplatin, and Nab-Paclitaxel Before Surgery in Patients With High-Risk Liver Bile Duct Cancer
Emory University
NCT02924376 COMPLETED Efficacy and Safety of Pemigatinib in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Who Failed Previous Therapy - (FIGHT-202)
Incyte Corporation
NCT05007106 COMPLETED MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)
Merck Sharp & Dohme LLC
NCT04057365 TERMINATED Study of the Combination of DKN-01 and Nivolumab in Previously Treated Patients With Advanced Biliary Tract Cancer (BTC)
Massachusetts General Hospital
NCT03314935 COMPLETED A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors
Incyte Corporation
NCT04571710 WITHDRAWN A Trial of SHR1258 in Patients With Biliary Tract Cancer
Jiangsu HengRui Medicine Co., Ltd.
NCT03377179 COMPLETED A Study of ABC294640 Alone and in Combination With HCQ Sulfate in the Treatment of Advanced Cholangiocarcinoma
RedHill Biopharma Limited
NCT04172402 COMPLETED NGS as the First-line Treatment in Advanced Biliary Tract Cancer
National Health Research Institutes, Taiwan
NCT05563272 TERMINATED 89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors
Telix Pharmaceuticals (Innovations) Pty Ltd
NCT03781934 COMPLETED A Study to Evaluate MIV-818 in Patients With Liver Cancer Manifestations
Medivir
NCT06370663 TERMINATED First-line Treatment for Unresectable Locally Advanced Distal Cholangiocarcinoma Combining Radiotherapy and HAIC
Shandong Cancer Hospital and Institute
NCT05253053 COMPLETED To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors
TransThera Sciences (Nanjing), Inc.
NCT03639935 COMPLETED Rucaparib in Combination With Nivolumab in Patients With Advanced or Metastatic Biliary Tract Cancer Following Platinum Therapy
University of Michigan Rogel Cancer Center
NCT03250273 COMPLETED A Clinical Trial of Entinostat in Combination With Nivolumab for Patients With Previously Treated Unresectable or Metastatic Cholangiocarcinoma and Pancreatic Adenocarcinoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT05251233 TERMINATED Role of Proton Pump Inhibitors on the Postoperative Course Following Pancreaticoduodenectomy
Washington University School of Medicine
NCT05239169 COMPLETED Immunotherapy With Durva and Treme With or Without Capecitabine in Adjuvant Treatment for Biliary Tract Cancer
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
NCT05565794 TERMINATED Pemigatinib After Curative Local Therapy in Advanced iCCA With FGFR2 Fusion/Rearrangements
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
NCT04383210 TERMINATED Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
Elevation Oncology
NCT02052778 COMPLETED A Study of TAS-120 in Patients With Advanced Solid Tumors
Taiho Oncology, Inc.
NCT04866836 TERMINATED A Study of Tislelizumab Combined With Radiotherapy as the Second-line Treatment of Advanced Biliary Malignant Tumors
The First Affiliated Hospital with Nanjing Medical University
NCT01862315 COMPLETED Hepatic Arterial Infusion (HAI) With Floxuridine (FUDR) and Dexamethasone (Dex) Combined With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma (ICC)
Memorial Sloan Kettering Cancer Center
NCT03058289 COMPLETED A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6
Intensity Therapeutics, Inc.
NCT01648023 COMPLETED Drug-Eluting Bead, Irinotecan Therapy for Unresectable Intrahepatic Cholangiocarcinoma w/Concomitant Gemcitabine and Cisplatin or Carboplatin
Robert C. Martin
NCT05010668 COMPLETED Cryoablation Combined With Sintilimab Plus Lenvatinib in Patients With Advanced Intrahepatic Cholangiocarcinoma
Fudan University
NCT04306367 COMPLETED Study of Pembrolizumab and Olaparib in Bile Duct Cancer
Georgetown University
NCT05236699 COMPLETED A Clinical Study of DEB-TACE Combined With Surufatinib and Camrelizumab in the Treatment of Inoperable or Metastatic ICC
Tongji Hospital
NCT04361331 COMPLETED Two-cohort Study of Toripalimab(PD1)+Lenvatnib, or Gemox+Lenvatinib in Advanced Intrahepatic Cholangiocarcinoma
Shanghai Zhongshan Hospital
NCT04492033 TERMINATED A Study of CTX-009 (ABL001) in Combination With Irinotecan or Paclitaxel in Advanced or Metastatic Solid Tumor Patients
Handok Inc.
NCT02878473 TERMINATED Liver Transplantation for Early Intrahepatic Cholangiocarcinoma
University Health Network, Toronto
NCT06017297 WITHDRAWN Neoadjuvant Tremelimumab and Durvalumab With Gem/Cis in Intrahepatic Cholangiocarcinoma
Georgetown University
NCT04989218 TERMINATED Durvalumab and Tremelimumab With Platinum-based Chemotherapy in Intrahepatic Cholangiocarcinoma (ICC)
University of Alabama at Birmingham
NCT05012397 TERMINATED Milademetan in Advanced/Metastatic Solid Tumors
Rain Oncology Inc
NCT04683939 TERMINATED Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT141 in Patients With Unresectable or Metastatic CLDN18.2-positive Gastric, Pancreatic, Ovarian and Biliary Tract Tumors
BioNTech SE
NCT05009953 TERMINATED Study of Irinotecan Liposome Injection in Patients With Advanced Biliary Tract Cancer
CSPC Ouyi Pharmaceutical Co., Ltd.
NCT04677504 COMPLETED A Study of Atezolizumab With or Without Bevacizumab in Combination With Cisplatin Plus Gemcitabine in Patients With Untreated, Advanced Biliary Tract Cancer
Hoffmann-La Roche
NCT04919642 COMPLETED Study to Evaluate the Efficacy and Safety of TT-00420 (Tinengotinib) in Cholangiocarcinoma
TransThera Sciences (Nanjing), Inc.
NCT05518071 COMPLETED FLUOPANC-trial - Fluorescence-guided Surgery of Pancreatic and Bileduct Tumors Using cRGD-ZW800-1
Leiden University Medical Center
NCT04256980 COMPLETED Pemigatinib in Treating Patients With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Rearrangement
Innovent Biologics (Suzhou) Co. Ltd.
NCT04742959 COMPLETED Study of TT-00420 (Tinengotinib) Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors
TransThera Sciences (Nanjing), Inc.
NCT02452970 TERMINATED RRx-001 in Second Line Treatment of Advanced Cholangiocarcinoma Prior to Readministration of First-Line Therapy
EpicentRx, Inc.
NCT03201458 COMPLETED Atezolizumab With or Without Cobimetinib in Treating Patients With Metastatic Bile Duct Cancer That Cannot Be Removed by Surgery or Gallbladder Cancer
National Cancer Institute (NCI)
NCT04059562 COMPLETED Trifluridine/Tipiracil in Combination With Irinotecan as a Second Line Therapy in Patients With Cholangiocarcinoma
Heinrich-Heine University, Duesseldorf
NCT03339843 COMPLETED Multiorgan Metabolic Imaging Response Assessment of Abemaciclib
Jules Bordet Institute
NCT03665285 COMPLETED A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors
NextCure, Inc.
NCT04720131 COMPLETED Camrelizumab Combined With Apatinib and Capecitabine in Patients With Advanced Biliary Tract Cancer.
Beijing Friendship Hospital
NCT03291899 TERMINATED Trial of Infusional FOLFIRINOX in First Line Treatment of Advanced Biliary Tract Cancers
King Faisal Specialist Hospital & Research Center
NCT05514912 WITHDRAWN Preoperative Nab-paclitaxel, Cisplatin, and Gemcitabine Chemotherapy With or Without Infigratinib Targeted Therapy for the Treatment of Resectable Intrahepatic Cholangiocarcinoma, The OPTIC Trial
Emory University
NCT03230318 COMPLETED Derazantinib in Subjects With FGFR2 Gene Fusion-, Mutation- or Amplification- Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma
Basilea Pharmaceutica
NCT03796429 COMPLETED A Study of the Efficacy and Safety of Chemotherapy Combined With Toripalimab in Advanced Biliary Tract Cancer
Shanghai Zhongshan Hospital
NCT03531320 COMPLETED Study of D07001-Softgel Capsules in Subjects With Gastrointestinal Cancer in Dose-Escalation Phase and in Subjects With Biliary Tract Cancer in Dose-Expansion Phase
InnoPharmax Inc.
NCT03684811 COMPLETED A Study of FT-2102 in Patients With Advanced Solid Tumors and Gliomas With an IDH1 Mutation
Forma Therapeutics, Inc.
NCT02232633 COMPLETED A Study of BBI503 in Adult Patients With Advanced Hepatobiliary Cancer
Sumitomo Pharma America, Inc.
NCT03260712 COMPLETED Pembrolizumab in Biliary Tract Cancer
European Organisation for Research and Treatment of Cancer - EORTC
NCT03833661 COMPLETED M7824 Monotherapy in Locally Advanced or Metastatic Second Line (2L) Biliary Tract Cancer (Cholangiocarcinoma and Gallbladder Cancer)
EMD Serono Research & Development Institute, Inc.
NCT04722133 COMPLETED Trastuzumab-pkrb Combined With Modified FOLFOX-6 in Biliary Tract Cancer Patients Progressed on First Line Therapy
Yonsei University
NCT02866383 COMPLETED Immune Checkpoint Inhibition in Combination With Radiation Therapy in Pancreatic Cancer or Biliary Tract Cancer Patients
Herlev Hospital
NCT03207347 COMPLETED A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001)
University of Florida
NCT04099888 TERMINATED PCI Treatment/Gemcitabine & Chemotherapy vs Chemotherapy Alone in Patients With Inoperable Extrahepatic Bile Duct Cancer
PCI Biotech AS
NCT03003065 COMPLETED Safety and Tumoricidal Effect of Low Dose Foscan PDT in Patients With Inoperable Bile Duct Cancers
Chinese University of Hong Kong
NCT04566133 TERMINATED Combination of Trametinib (MEK Inhibitor) and Hydroxychloroquine (HCQ) (Autophagy Inhibitor) in Patients With KRAS Mutation Refractory Bile Tract Carcinoma (BTC).
National Cancer Institute (NCI)
NCT04072445 COMPLETED Trifluridine/Tipiracil and Irinotecan for the Treatment of Advanced Refractory Biliary Tract Cancer
Mayo Clinic
NCT04644315 TERMINATED A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors
Hoffmann-La Roche
NCT03602079 COMPLETED Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene
Klus Pharma Inc.
NCT02150967 TERMINATED A Phase II, Single Arm Study of BGJ398 in Patients With Advanced Cholangiocarcinoma
QED Therapeutics, a BridgeBio company
NCT05116891 COMPLETED A Phase 1/2 Study of CAN04 in Combination With Different Chemotherapy Regimens in Subjects With Advanced Solid Tumors
Cantargia AB
NCT03278106 COMPLETED TAS-102 in Treating Advanced Biliary Tract Cancers
Mayo Clinic
NCT04217954 COMPLETED HAIC With Oxaliplatin, 5-FU and Bevacizumab Plus Intravenous Toripalimab for Advanced BTC
Peking University
NCT03679338 COMPLETED Prospective Evaluation of the Ablation Therapy With Bipolar Radio Frequency for Nonresectable Bile Duct Cancer
Institut Paoli-Calmettes
NCT03473574 COMPLETED Durvalumab and Tremelimumab With Gemcitabine or Gemcitabine/Cisplatin Compared to Gemcitabine/Cisplatin in CCA Patients
AIO-Studien-gGmbH
NCT02520141 COMPLETED Ramucirumab in Treating Patients With Advanced or Metastatic, Previously Treated Biliary Cancers That Cannot Be Removed by Surgery
M.D. Anderson Cancer Center
NCT03999658 WITHDRAWN A Study of STI-3031 (an Anti-PD-L1 Antibody) in Patients With Selected Relapsed/Refractory Malignancies
Sorrento Therapeutics, Inc.
NCT03790111 TERMINATED A Safety and Efficacy Study of XERMELO® + First-line Chemotherapy in Patients With Advanced Biliary Tract Cancer
TerSera Therapeutics LLC
NCT03895970 COMPLETED Lenvatinib Combined Pembrolizumab in Advanced Hepatobiliary Tumors
Peking Union Medical College Hospital
NCT02821754 COMPLETED A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC)
National Cancer Institute (NCI)
NCT03801915 COMPLETED Perioperative MVT-5873, a Fully Human Monoclonal Antibody Against a CA 19-9 Epitope, for Operable CA 19-9 Producing Pancreatic Cancers, Cholangiocarcinomas, and Metastatic Colorectal Cancers
National Cancer Institute (NCI)
NCT04784520 TERMINATED A Study of HA121-28 Tablets in Advanced Biliary Tract Cancer
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
NCT02393248 TERMINATED Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)
Incyte Corporation
NCT03079427 COMPLETED Adjuvant Capecitabine vs Gemcitabine Plus Cisplatin in Resected Extrahepatic Cholangiocarcinoma
Asan Medical Center
NCT04076761 TERMINATED Study of TRIFLURIDINE/TIPIRACIL in Previously Treated Cholangiocarcinoma
Sunnybrook Health Sciences Centre
NCT02415036 TERMINATED Melphalan for Use With the Hepatic Delivery System Treatment in Patients With Unresectable Hepatocellular Carcinoma or Intra Hepatic Cholangiocarcinoma
Delcath Systems Inc.
NCT03769753 COMPLETED Trial of IRE in Cholangiocarcinoma
Memorial Sloan Kettering Cancer Center
NCT03524508 COMPLETED Nal-IRI(Nanoliposomal Irinotecan) Plus 5-FU/LV in Metastatic Biliary Tract Cancer
Changhoon Yoo
NCT04895046 WITHDRAWN Maintenance Niraparib and Dostarlimab in Advanced Cholangiocarcinoma
Walid Shaib, MD
NCT03110510 WITHDRAWN FOLFIRI as Salvage Treatment in Metastatic Biliary Tract Cancer (BTC) Patients Who Were Failed After Gemcitabine Containing Chemotherapy: A Phase II Single Arm Prospective Study
Samsung Medical Center
NCT03110328 COMPLETED Study of Pembrolizumab in Metastatic Biliary Tract Cancer as Second-line Treatment After Failing to at Least One Cytotoxic Chemotherapy Regimen: Integration of Genomic Analysis to Identify Predictive Molecular Subtypes
Samsung Medical Center
NCT04546828 WITHDRAWN A Single-arm Study of Gemcitabine, Cisplatin, and Nab-Paclitaxel as Neoadjuvant Therapy for Resectable Oncologically High-Risk IHCC in Korea
Samsung Medical Center
NCT04796454 WITHDRAWN Pamiparib and Low Dose Temozolomide In Patients With Platinum Sensitive Biliary Tract Cancer
European Organisation for Research and Treatment of Cancer - EORTC
NCT04727541 TERMINATED Neoadjuvant Bintrafusp Alfa in Patients With Resectable Biliary Tract Cancer
AIO-Studien-gGmbH
NCT03043547 COMPLETED Nal-IRI and 5-FU Compared to 5-FU in Patients With Cholangio- and Gallbladder Carcinoma Previously Treated With Gemcitabine-based Therapies
AIO-Studien-gGmbH
NCT03316222 TERMINATED Study of GNS561 in Patients With Liver Cancer
Genoscience Pharma
NCT05019677 WITHDRAWN GP Chemotherapy in Combination With Tislelizumab and Ociperlimab as First-line Treatment in Advanced BTC
Fudan University
NCT03937895 COMPLETED Allogeneic NK Cell ("SMT-NK") in Combination With Pembrolizumab in Advanced Biliary Tract Cancer
SMT bio Co., Ltd.
NCT04648319 TERMINATED A Study of BMS-936558 With SBRT After Induction Chemotherapy in Cholangiocarcinoma
American University of Beirut Medical Center
NCT02982720 TERMINATED Evaluating Combination Immunotherapy for Advanced Cholangiocarcinoma With Pembrolizumab and PEG-Intron
Aiwu Ruth He, MD
NCT02392637 COMPLETED Gemcitabine Hydrochloride, Cisplatin, and Nab-Paclitaxel in Treating Patients With Advanced or Metastatic Biliary Cancers
M.D. Anderson Cancer Center
NCT03111732 COMPLETED Pembrolizumab, a Monoclonal Antibody Against PD-1, in Combination With Capecitabine and Oxaliplatin (CAPOX) in People With Advanced Biliary Tract Carcinoma (BTC)
National Cancer Institute (NCI)
NCT03486678 COMPLETED SHR-1210 in Combination With GEMOX in Patients With Advanced BTC
The First Affiliated Hospital with Nanjing Medical University
NCT02128282 COMPLETED Study of CX-4945 in Combination With Gemcitabine and Cisplatin for Frontline Treatment of Cholangiocarcinoma
Senhwa Biosciences, Inc.
NCT02631590 COMPLETED Copanlisib (BAY 80-6946) in Combination With Gemcitabine and Cisplatin in Advanced Cholangiocarcinoma
H. Lee Moffitt Cancer Center and Research Institute
NCT04479904 WITHDRAWN A Trial of Famitinib in Patients With Failure of First-Line Treatment For Intrahepatic Cholangiocarcinoma
Jiangsu HengRui Medicine Co., Ltd.
NCT04656249 COMPLETED Lenvatinib in Patients With Previously Treated Advanced Biliary Tract Cancer
Peking Union Medical College Hospital
NCT04642664 COMPLETED Apatinib Plus Camrelizumab in Patients With Previously Treated Advanced Biliary Tract Cancer
Peking Union Medical College Hospital
NCT02273739 COMPLETED Study of Orally Administered Enasidenib (AG-221) in Adults With Advanced Solid Tumors, Including Glioma, or Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation
Celgene
NCT03778593 COMPLETED FOLFIRINOX for 2nd-line Treatment of BTC
Dong-A University Hospital
NCT04186156 WITHDRAWN A Study of Selective HDAC6 Inhibition With KA2507 in Advanced Biliary Tract Cancer
Karus Therapeutics Limited
NCT03830606 COMPLETED The Efficacy and Safety of Nab-paclitaxel Plus S-1 in First-line Treatment of Advanced Biliary Tract Adenocarcinoma
Aiping Zhou
NCT02992340 TERMINATED Varlitinib in Combination With Gemcitabine and Cisplatin for Treatment naïve Advanced or Metastatic BTC
ASLAN Pharmaceuticals
NCT03613168 COMPLETED Trastuzumab in HER2-positive Biliary Tract Cancer
Changhoon Yoo
NCT02579616 COMPLETED Study of Lenvatinib (E7080) in Unresectable Biliary Tract Cancer (BTC) Who Failed Gemcitabine-based Combination Chemotherapy
Eisai Co., Ltd.
NCT03251443 COMPLETED A Study of Second-line Treatment With Apatinib in Patients With Advanced Intrahepatic Cholangiocarcinoma
Peking Union Medical College Hospital
NCT03231176 COMPLETED Varlitinib Plus Capecitabine in Chinese Patients With Advanced or Metastatic Biliary Tract Cancer
ASLAN Pharmaceuticals
NCT01247337 COMPLETED Intra-hepatic Chemotherapy in Patient With Non-resectable Liver Metastases From Cholangiocarcinoma
Dorte Nielsen
NCT02428855 COMPLETED Phase II Trial of Dasatinib in Patients With Isocitrate Dehydrogenase (IDH)-Mutant Advanced Intrahepatic Cholangiocarcinoma
Massachusetts General Hospital
NCT03801499 WITHDRAWN Lenvatinib for Unresectable Intrahepatic Cholangiocarcinoma
Sun Yat-sen University
NCT03768531 WITHDRAWN Safety and Tolerability Study of Nivolumab and Cabiralizumab for Resectable Biliary Tract Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT00948935 COMPLETED Study of Gemcitabine, Irinotecan and Panitumumab in Patients With Advanced and Metastatic Biliary Tract Adenocarcinoma
Abramson Cancer Center at Penn Medicine
NCT02456714 COMPLETED Second Line Chemotherapy FOLFIRINOX in Irresectable Cholangiocarcinoma
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
NCT00779454 COMPLETED Combined Biological Treatment and Chemotherapy for Patients With Inoperable Cholangiocarcinoma
Vejle Hospital
NCT03818997 WITHDRAWN Combination of Targeted and Immunotherapy for Advanced Biliary Tract and Esophagogastric Gastric Cancer
European Organisation for Research and Treatment of Cancer - EORTC
NCT02496741 COMPLETED Metformin And Chloroquine in IDH1/2-mutated Solid Tumors
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
NCT02994251 TERMINATED A Trial of Systemic Chemotherapy in Combination With Conventional Transarterial Chemoembolization in Patients With Advanced Intra-Hepatic Cholangiocarcinoma
Yale University
NCT02773459 COMPLETED MEK162 in Combination With Capecitabine in Advanced Biliary Tract Cancer
Seoul National University Hospital
NCT02425137 COMPLETED A Study of S-1 in Combination With Gemcitabine as First-Line Treatment in Patients With Advanced Biliary Tract Cancer
TTY Biopharm
NCT02955771 TERMINATED Efficacy and Safety Study of PDT Using Deuteporfin for Unresectable Advanced Perihilar Cholangiocarcinoma
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
NCT01766219 COMPLETED CPI-613 in Treating Patients With Advanced or Metastatic Bile Duct Cancer That Cannot Be Removed By Surgery
Wake Forest University Health Sciences
NCT01290536 COMPLETED Yttrium-90 Radioembolization Using Glass Microspheres (TheraSphere) for Patients With Liver Metastases
Nicholas Fidelman, MD
NCT02966821 COMPLETED Study of Surufatinib as Second-line Treatment in Patients With Biliary Tract Carcinoma
Hutchison Medipharma Limited
NCT01917617 COMPLETED Oral Rehydration Therapy for Short Hydration in Chemotherapy With CDDP Plus GEM for Biliary Tract Cancer
Kansai Hepatobiliary Oncology Group
NCT03779100 SUSPENDED Lenvatinib Plus PD-1 Antibody for Unresectable ICC
Shi Ming
NCT01855724 TERMINATED Clinical Trial to Investigate the Efficacy of Treatment With Gemcitabine/Pazopanib in Patients With Biliary Tree Cancer
Hellenic Cooperative Oncology Group
NCT02254681 TERMINATED Low-Dose Radiation Therapy to the Whole Liver With Gemcitabine and Cisplatin in IHC
Allina Health System
NCT02181634 COMPLETED Phase II Trial of Nab-Paclitaxel and Gemcitabine for First-Line Treatment of Patients With Cholangiocarcinoma
PrECOG, LLC.
NCT02433639 COMPLETED Study of TH-302 Monotherapy as Second-line Treatment in Advanced Biliary Tract Cancer
Seoul National University Hospital
NCT02609958 COMPLETED ASLAN001 in Patients With Advanced or Metastatic Cholangiocarcinoma Who Progressed on at Least 1 Line of Systemic Therapy
ASLAN Pharmaceuticals
NCT03129074 WITHDRAWN Study of Varlitinib Plus Capecitabine in Patients With Advanced or Metastatic Biliary Tract Cancer
ASLAN Pharmaceuticals
NCT01815307 COMPLETED Phase II Study of Gemcitabine Versus S-1 Adjuvant Therapy After Hemihepatectomy for Biliary Tract Cancer
Kansai Hepatobiliary Oncology Group
NCT01912053 COMPLETED Efficacy Study of Intra-hepatic Administration of Therasphere® in Association With Intravenous Chemotherapy to Treat Cholangiocarcinoma
Center Eugene Marquis
NCT00789958 COMPLETED S0809: Capecitabine, Gemcitabine, and RT in Patients w/Cholangiocarcinoma of the Gallbladder or Bile Duct
SWOG Cancer Research Network
NCT02374489 TERMINATED A Phase II Trial of LDK378 in ROS1 and /or ALK Over-expressed Advanced Intrahepatic or Hilar Cholangiocarcinoma
National Health Research Institutes, Taiwan
NCT02638909 TERMINATED Study of Oral Ceritinib in Patients With ALK and ROS1 Activated Gastrointestinal Malignancies
Criterium, Inc.
NCT01963325 COMPLETED S-1 in Combination With Abraxane in Treating Cholangiocarcinoma
Yuhong Li
NCT02720601 WITHDRAWN Irinotecan and Capecitabine as Second-line Treatment for Advanced/Metastatic Biliary Tract Cancers
New Mexico Cancer Research Alliance
NCT00955721 TERMINATED A Study of Combination of Gemcitabine, Oxaliplatin (GEMOX)-Sorafenib in Patients With Advanced Biliary Tract Cancer
University of Miami
NCT01043172 COMPLETED A Study of Gemcitabine as an Adjuvant Treatment for Cholangiocarcinoma After Surgical Resection
National Cancer Center, Korea
NCT00903396 TERMINATED Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
Alliance for Clinical Trials in Oncology
NCT02042443 COMPLETED Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
NCT02346032 COMPLETED Phase II Study of Refametinib, a MEK Inhibitor, as Second-line Treatment in Advanced Biliary Tract Adenocarcinoma
Samsung Medical Center
NCT01229111 TERMINATED Cediranib Maleate and Combination Chemotherapy in Treating Patients With Advanced Biliary Cancers
National Cancer Institute (NCI)
NCT01007552 COMPLETED A Study of Gemcitabine, Capecitabine and Bevacizumab to Treat Cancer of the Gall Bladder or Bile Ducts
Roswell Park Cancer Institute
NCT01206049 COMPLETED Combination Chemotherapy Plus Panitumumab or Bevacizumab for Inoperable Cholangiocarcinoma Without KRAS Mutations
Vejle Hospital
NCT01954745 COMPLETED Cabozantinib (XL-184) Monotherapy for Advanced Cholangiocarcinoma
Massachusetts General Hospital
NCT01718327 COMPLETED A Study of Sunitinib in Patients With Advanced Cholangiocarcinoma
GERCOR - Multidisciplinary Oncology Cooperative Group
NCT01572324 COMPLETED Study of Hepatic Arterial Infusion to Treat Biliary Tract Carcinomas
Peking University
NCT00753675 COMPLETED Vandetanib Gemcitabine Or Placebo Plus Gemcitabine Or Vandetanib Monotherapy In Advanced Biliary Tract Cancer
Genzyme, a Sanofi Company
NCT01308840 COMPLETED Gemcitabine, Oxaliplatin and Panitumumab in Kras/B-raf Wild-Type Biliary Track and Gallbladder Cancer
University of Rochester
NCT01151761 TERMINATED Phase II SBRT & Chemo for Unresectable Cholangiocarcinoma Followed by Liver Transplantation
Stanford University
NCT01425879 COMPLETED MK2206 in Treating Patients With Advanced Refractory Biliary Cancer That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
NCT02468076 COMPLETED Radiofrequency Ablation for Biliopancreatic Malignancy
Universitaire Ziekenhuizen KU Leuven
NCT01267344 COMPLETED A Randomized Study of GEMOX With or Without Cetuximab in Locally Advanced and Metastatic BTC
National Health Research Institutes, Taiwan
NCT00975039 TERMINATED Study Using WST11 in Patients With Non-Resectable or Inoperable Cholangiocarcinoma
Steba Biotech S.A.
NCT02479178 TERMINATED A Study of BIND-014 in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck
BIND Therapeutics
NCT02683538 COMPLETED Radiofrequency Ablation Using Octopus Electrodes for Treatment of Focal Liver Malignancies
Seoul National University Hospital
NCT01530503 COMPLETED Second Line Therapy in Advanced Biliary Tract Cancer
IRCCS San Raffaele
NCT00919061 COMPLETED Gemcitabine and Cisplatin Plus Sorafenib in Patients With Advanced Biliary Tract Carcinomas Naive to Systemic Therapy
Memorial Sloan Kettering Cancer Center
NCT01501604 WITHDRAWN BKM120 in Cancers With PIK3CA Activating Mutations
Massachusetts General Hospital
NCT01093222 COMPLETED Sorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gallbladder Cancer or Cholangiocarcinoma
National Cancer Institute (NCI)
NCT01775280 WITHDRAWN Response of Hepatic Tumors to Radioembolization
University of Zurich
NCT00881504 TERMINATED A Study of FOLFOX6 With Bevacizumab for Biliary System Carcinoma
Georgetown University
NCT01859182 WITHDRAWN Selumetinib and Akt Inhibitor MK-2206 in Treating Patients With Refractory or Advanced Gallbladder or Bile Duct Cancer That Cannot Be Removed By Surgery
National Cancer Institute (NCI)
NCT01284413 COMPLETED Gemcitabine/Cisplatin/S-1(GCS) Combination Therapy for Patients With Advanced Biliary Tract Cancer
Kansai Hepatobiliary Oncology Group
NCT01171755 TERMINATED Phase II Study of Gemcitabine and TS-1 in Biliary Trat Cancer
Samsung Medical Center
NCT01127555 COMPLETED Salvage mFOLFOX in BTC After Failure of Gemcitabine
Chung-Ang University
NCT00959946 TERMINATED Study Of Bosutinib With Capecitabine In Solid Tumors And Locally Advanced Or Metastatic Breast Cancer
Pfizer
NCT00713687 WITHDRAWN Gemcitabine/Oxaliplatin and Photodynamic Therapy in Cholangiocarcinoma
Technical University of Munich
NCT01096745 TERMINATED Randomized Trial of Gemcitabine/Cisplatin Versus S-1/Cisplatin in Advanced Biliary Cancer
Gyeongsang National University Hospital
NCT00832689 COMPLETED Irinotecan, Gemcitabine, Chemotherapy for Biliary Tract Cancer
Yonsei University
